Trevena, Inc. (NASDAQ:TRVN – Get Free Report) passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $0.01 and traded as low as $0.0010. Trevena shares last traded at $0.0010, with a volume of 1,844 shares changing hands.
Trevena Stock Down 91.0%
The company has a 50-day moving average of $0.01 and a 200 day moving average of $0.01. The stock has a market capitalization of $959.00, a PE ratio of -0.00 and a beta of 0.18.
About Trevena
Trevena, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of biased ligand G protein-coupled receptor (GPCR) selective medicines. By leveraging its proprietary bias-ligand technology platform, Trevena aims to create therapies that preferentially activate beneficial signaling pathways while minimizing engagement of pathways linked to adverse effects. The company’s research efforts target areas of high unmet medical need, including pain management, cardiometabolic disorders and central nervous system conditions.
The company’s lead compound, oliceridine (also known by its brand name OLINVEO), is a G protein-biased μ-opioid receptor agonist designed for the treatment of moderate to severe acute pain in the hospital setting.
Featured Articles
- Five stocks we like better than Trevena
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.
